Questions on asparaginase-associated pancreatitis

Since its earliest conceptions by Emil Frei, Emil Freireich, and colleagues,1 the successful development of combination chemotherapy for young patients with acute lymphoblastic leukaemia has served as a sustained model for all other tumour types for all patients in the modern era of cancer therapy. With substantially improved outcomes with these multi-agent combination chemotherapy regimens from the 1960s to the present time in children with acute lymphoblastic leukaemia, more attention is now being placed on adolescents and young adults—an in-between group of patients with unique characteristics, patterns of adherence, and concerns for short-term and long-term chemotherapy-related toxicities.